Effects of monensin in supplements for beef cattle in tropical grazing systems during the rainy season.

Two experiments were carried out to evaluate the effect of monensin in supplements for grazing heifers. In experiment I, treatments consisted of protein supplements (low intake - 0.5 kg/animal/day and high intake - 1.0 kg/animal/day) associated or not with monensin. Animal performance, nutrient intake, and digestibility were evaluated. Forty crossbred heifers with an initial body weight (BW) of 213.8 ± 4.5 kg were used. There was no difference in average daily gain between treatments (average of 0.588 kg/animal/day). There was no interaction between monensin and supplements for intake parameters and digestibility. Dry matter (DM) intake was equal between treatments (~ 2% of BW). However, there was a reduction in pasture intake with the high-intake supplement. In experiment II, treatments consisted of two types of supplements (protein or mineral) associated or not with monensin. The variables analyzed were productive performance, ingestive behavior, and thermal comfort, evaluated through the index of thermal stress for cows (ITSC). Forty crossbred heifers with a BW of 159.2 ± 1.3 kg were used. The type of supplement did not influence the performance of the animals. However, monensin promoted greater weight gain in the animals (110 g/animal/day). There was an interaction effect between supplementation and monensin addition on behavioral activities, except for idle time. The inclusion of monensin in the protein supplement reduced the grazing time. The ITSC value influenced the activities of ingestive behavior, and the increase of this index reduced the grazing time in all treatments. Forage quality influences the response to monensin use, and the addition of monensin in supplements for grazing cattle during the rainy season is recommended for forages with high CP content.

A Review of "Polychaeta" Chemicals and their Possible Ecological Role.

Despite the many publications concerning the isolation of substances and the many reviews of marine natural products, some groups of organisms remain poorly studied, including "Polychaeta". In response, this review covers articles published through December 2016 that address marine natural products produced from polychaetes, with a focus on antipredatory strategies, competitors, fouling, and pathogens. A total of 121 compounds were isolated from 1934 to 2016, which includes halogenated aromatics, proteins, amino acids and Lumazine derivatives most notably-with a defensive function were found in the literature, most frequently in the families Sabellidae, Terebellidae, Glyceridae, and Nereididae. The period of highest discovery of natural products in defensive actions for the group was the 2000s. Polychaetes were addressed in 26 revisions of the total 51 articles analyzed and are less reported than other marine invertebrates such as sponges, cnidarians, mollusks, and tunicates. In sum, the present review provides a basis for future research on the marine chemical ecology of polychaetes.

Palatability and Physical and Chemical Defenses in Five Annelid Polychaetes from Tropical Brazilian Beaches.

AbstractAlthough researchers have examined numerous marine organisms' compensatory characteristics to minimize predation pressure, few have investigated the defensive mechanisms of polychaetes, despite their diversity. Thus, our study's aim was to evaluate the palatability and defensive strategies, both chemical and structural, in the polychaetes Branchiomma luctuosum, Perinereis anderssoni, Phragmatopoma caudata, Eurythoe complanata, and Timarete sp. Another twofold aim was to determine, by comparing our results with the literature, any latitudinal difference in the defensive strategies of E. complanata and to assess defensive mechanisms and palatability in relation to individuals' mobility, overtness, body regionalization, and color. Specimens were collected at Boa Viagem and Itaipu Beaches in Niterói, Rio de Janeiro, Brazil. In assays, a generalist consumer, the hermit crab Calcinus tibicen, was used to evaluate palatability and defenses. In palatability assays of live tissue of the polychaetes, consumers were offered a fresh piece of each polychaete to gauge their acceptance or rejection; in artificial food assays to test extracts of the polychaetes, artificial bait containing extracts of the polychaetes was offered to crabs to identify any chemical defense. Although the extracts of B. luctuosum, E. complanata, P. caudata (i.e., opercular crown), and Timarete sp. were not palatable to the consumers, extracts of P. anderssoni and P. caudata (i.e., body) were. Moreover, the opercular crown of P. caudata and the branchial crown of B. luctuosum showed evidence of structural and chemical defenses. The results corroborate past findings, suggesting no latitudinal variation in the defensive strategies of E. complanata. In general, less motile and more exposed species, aposematic or dark in color, exhibited greater investment in defensive strategies and unpalatability.

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.

CONTEXT: Type 1 diabetes mellitus (DM) results from a cell-mediated autoimmune attack against pancreatic beta cells. Previous animal and clinical studies suggest that moderate immunosuppression in newly diagnosed type 1 DM can prevent further loss of insulin production and can reduce insulin needs. OBJECTIVE: To determine the safety and metabolic effects of high-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) in newly diagnosed type 1 DM. DESIGN, SETTING, AND PARTICIPANTS: A prospective phase 1/2 study of 15 patients with type 1 DM (aged 14-31 years) diagnosed within the previous 6 weeks by clinical findings and hyperglycemia and confirmed with positive antibodies against glutamic acid decarboxylase. Enrollment was November 2003-July 2006 with observation until February 2007 at the Bone Marrow Transplantation Unit of the School of Medicine of Ribeirão Preto, Ribeirão Preto, Brazil. Patients with previous diabetic ketoacidosis were excluded after the first patient with diabetic ketoacidosis failed to benefit from AHST. Hematopoietic stem cells were mobilized with cyclophosphamide (2.0 g/m2) and granulocyte colony-stimulating factor (10 microg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were injected intravenously after conditioning with cyclophosphamide (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg). MAIN OUTCOME MEASURES: Morbidity and mortality from transplantation and temporal changes in exogenous insulin requirements (daily dose and duration of usage). Secondary end points: serum levels of hemoglobin A1c, C-peptide levels during the mixed-meal tolerance test, and anti-glutamic acid decarboxylase antibody titers measured before and at different times following AHST. RESULTS: During a 7- to 36-month follow-up (mean 18.8), 14 patients became insulin-free (1 for 35 months, 4 for at least 21 months, 7 for at least 6 months; and 2 with late response were insulin-free for 1 and 5 months, respectively). Among those, 1 patient resumed insulin use 1 year after AHST. At 6 months after AHST, mean total area under the C-peptide response curve was significantly greater than the pretreatment values, and at 12 and 24 months it did not change. Anti-glutamic acid decarboxylase antibody levels decreased after 6 months and stabilized at 12 and 24 months. Serum levels of hemoglobin A(1c) were maintained at less than 7% in 13 of 14 patients. The only acute severe adverse effect was culture-negative bilateral pneumonia in 1 patient and late endocrine dysfunction (hypothyroidism or hypogonadism) in 2 others. There was no mortality. CONCLUSIONS: High-dose immunosuppression and AHST were performed with acceptable toxicity in a small number of patients with newly diagnosed type 1 DM. With AHST, beta cell function was increased in all but 1 patient and induced prolonged insulin independence in the majority of the patients.

Transplante de células-tronco hematopoéticas em doencas reumáticas parte 1: experiência internacional / Hematopoietic stem cell transplantation for rheumatic diseases part 1: international experience

Nesta revisão, discutem-se os resultados dos transplantes de células-tronco hematopoéticas (TCTH) para doencas reumáticas graves e refratárias à terapia convencional realizados no exterior. Revêem-se brevemente as bases clínicas e experimentais para a realizacão desses transplantes e os resultados internacionais obtidos em lúpus eritematoso sistêmico (LES) (33/50 remissões completas no registro europeu, com dez recidivas posteriores e 12 óbitos; 41/45 remissões duradouras em um centro americano, com dois óbitos pós-mobilizacão e quatro óbitos pós-transplante), artrite reumatóide (AR) do adulto (58/73 remissões parciais com 85 por cento de recidivas posteriores e apenas um óbito no registro europeu), artrite idiopática juvenil (AIJ) (18/34 remissões duradouras e cinco óbitos no registro europeu), esclerose sistêmica (ES) (46/50 respostas em um estudo europeu multicêntrico, com 35 por cento de recidivas e 23 por cento de mortalidade, enquanto num estudo americano, houve quatro óbitos e duas pneumopatias progressivas dentre 19 pacientes e melhora cutânea e da qualidade de vida em todos os sobreviventes) e em uma miscelânea de outras doencas, incluindo as vasculites (9/15 respostas completas no registro europeu). Conclui-se que, na experiência internacional, o TCTH autólogo induz remissões prolongadas na maioria das doencas graves e refratárias em que foi utilizado, com excecão da AR do adulto, justificando o início de estudos prospectivos randomizados comparando-o com a terapia convencional otimizada.

Transplante de células-tronco hematopoéticas em doencas reumáticas. Parte 2: experiência brasileira e perspectivas futuras / Hematopoietic stem cell transplantation for rheumatic diseases. Part 2: brazilian experience and future prospectives

Nesta revisão, discutem-se os resultados dos transplantes de células-tronco hematopoéticas (TCTH) para doencas reumáticas graves e refratárias à terapia convencional realizados no Brasil. São analisados os resultados preliminares obtidos no Brasil com o TCTH autólogo em casos esporádicos (N=3) e no protocolo cooperativo iniciado em 2001 (N=18). Neste protocolo, dentre os 8 casos de nefrite lúpica, houve 3 remissões sustentadas, 3 óbitos, 1 falha de mobilizacão e 1 seguimento ainda muito curto; entre os 7 de esclerose sistêmica, houve 3 remissões após o TCTH e 2 após mobilizacão, um óbito pós-mobilizacão das CTH e outro após a primeira dose do condicionamento, este último em uma superposicão com LES; em dois pacientes com vasculite, houve uma remissão em arterite de Takayasu e outra em doenca de Behcet; uma paciente com artrite inflamatória juvenil foi incluída muito recentemente no protocolo. O seguimento dos pacientes sobreviventes variou de 0 a 48 meses, com uma mediana de 29 meses. Conclui-se com uma discussão do custo-benefício do TCTH em face das novas formas de imunossupressão disponíveis e das perspectivas futuras em países desenvolvidos, onde se iniciaram recentemente estudos prospectivos randomizados comparando o transplante com a melhor terapia medicamentosa disponível, e no Brasil, onde o custo do transplante é muito inferior ao das novas terapias biológicas.

Diagnóstico e tratamento de complicaçöes agudas do transplante de células progenitoras hematopoéticas / Diagnosis and treatment of acute complications of hematopoietic stem cell transplantation

Nesta revisäo, säo discutidos os princípios do diagnóstico e tratamento das principais complicaçöes agudas, näo infecciosas, do transplante de células progenitoras hematopoéticas: pancitopenia, incompatibilidade no sistema ABO, mucosite, doença veno-oclusiva hepática, cistite hemorrágica, penumonite intersticial, cardiotoxicidade e doença do enxerto-contra-hospedeiro aguda. Oito casos clínicos, extraídos da casuística da nossa Unidade de TMO, säo descritos brevemente para ilustrar aspectos particulares das doenças discutidas no trabalho.

Transplante autólogo de células tronco hematopoéticas para nefite lúpica: resultados brasileiros iniciais / Autologous hematopoietic stem cell transplantation for lupus nephritis: preliminary results in Brazil

Objetivo :Relatar a evolução clínico-laboratorial dos quatro primeiros pacientes portadores de nefrite lúpica submetidos a transplante autálogo de células tronco hematopoéticas (TCTH), no Brasil, dentro de um protocolo cooperativo multicêntrico. Métodos: Pacientes com nefrite lúpica refratária a, pelo menos, seis pulsos de ciclofosfarnida EV, tiveraram suas CTH mobilizadas da medula óssea para o sangue periférico com ciclofosfamida (2 g/m') e G-CSF, coletadas por leucocitoaférese e criopreservadas em nitrogênio líquido. Após a recuperação hematopoética, foram condicionados com uma dose maior de ciciofosfamida (200 mg/kg) e globulina antitimocitária (ATG) de cavalo (1 5 mglkg), administrada 3 vezes antes e após a infusão das células tronco hematopoéticas autálogas. Os pacientes foram mantidos em isolamento protetor, durante o período pancitopênico, e acompanhados ambulatorialmente, após o enxertamento hematopoético. Resultados :Três pacientes tiveram insuficiência renal com sobrecarga hídrica significativa durante o condicionamento, requerendo hemodiálise e um paciente foi a óbito em consequencia dessas complicações. Os três pacientes sobreviventes obtiveram remissão da doença renal após o transplante (três a 13 meses de seguimento). Conclusões :Os resultados iniciais ilustram os riscos e o potencial benefício do procedimento e estimulam a extensão da experiência a um número maior de pacientes.